All News

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.

Of all the things that cancer left me with, scarred veins in my only good arm has been the worst. I have learned to treasure those techs who can find a good vein and hit it the first time.

The importance of teamwork between patients and their caregivers was a common theme at the second annual Ovarian Cancer Heroes event held in Honolulu, Hawaii.

The Childhood Solid Tumor Network at St. Jude is helping scientists inside and outside the hospital’s walls to expand treatment options for youngsters with these cancers.

A caregiver's view on why this bill needs careful consideration.

From FDA news to today’s top performers and entertainers, here’s what’s making headlines in the cancer space this week.

One is meant to improve quality of life and the other is meant to care for end-of-life. Yet the two specialties of palliative and hospice care still continue to be confused not only by the patient, but also the provider.

With the evolving landscape of maintenance therapies to treat patients with lymphoma following auto-HCT, a panel consensus recommended four grade A options for physicians to utilize.

An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.

Every person handles a cancer diagnosis differently. The most important thing is that you say or do something. Here are three suggestions you may find helpful based on my experience.

Connect yourself to items that can help you through your cancer journey.

A cancer gene panel using blood may be a cost-effective way of testing the quantity of mutations found in tumors of patients with non-small cell lung cancer.

Women with frequent urinary tract infections (UTIs) were more likely to experience lower quality diagnostic processes when it comes to screening for bladder and kidney cancer.

Although muscle-invasive disease is often treated by removal of the bladder, experts reveal potential high risk of death.

St. Jude Children’s Research Hospital is offering cloud-based access to the fully sequenced genomes of 10,000 pediatric patients with cancer, in the hopes that sharing the information will lead to the highest possible number of treatment breakthroughs.

As a breast cancer survivor, I have become more active in my efforts to call attention to problems with secondhand smoke in my community. Since I know that exposure is not healthy, lobbying for changes in attitudes, as well as policies, makes me feel more empowered.

At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.

Rose Gerber, of the Community Oncology Alliance, shared her story of participating in a clinical trial and hopes for others to help educate patients with breast cancer to increase participation moving forward.

At CURE’s patient-focused meeting at the 36th Annual Miami Breast Cancer Conference, Shannon Pulaski and Ellen Matloff discussed the importance of genetic counseling and learning more about one’s family health history.

Helping others is the last phase of recovery.

The Food and Drug Administration (FDA) has granted an approval to Trazimera (PF-05280014; trastuzumab-qyyp), a Herceptin (trastuzumab) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Many people believe that genetic testing for cancer can only be beneficial for individuals with a strong family history of the disease, but that is not necessarily the case.

Can at-home DNA testing kits accurately help us discover important health information? What do we do with the information once we receive it? In this post, learn more about the pros and cons.

In conjunction with Kidney Cancer Awareness Month, learn more about risk factors and treatment options for the disease.

After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.

The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.